IMPEDE-VTE

Loading...

Immunomodulatory drug use

BMI ≥ 25 kg/m2

Pelvic, hip or femur fracture

Erythropoiesis-stimulating agent

Doxorubicin use

Dexamethasone use

Ethnicity/race is Asian/Pacific Islander

History VTE before MM

Tunneled line/central venous catheter

Existing thromboprophylaxis: therapeutic LMWH or warfarin use

Existing thromboprophylaxis: prophylactic LMWH or aspirin use

References

A Falanga. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.. Annals of oncology : official journal of the European Society for Medical Oncology, 2023
M. Alexander. Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.. JAMA oncology, 2023
Kristen M. Sanfilippo. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. American Journal of Hematology, 2019
M. Carrier. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. The New England Journal of Medicine, 2019
Nigel S Key. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019
F. Covut. External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2019